www.hepatology-d	ruginteractions.org		UNIVERSITY OF LIVERPOOL
		Interaction Report	
Report ID: Date Produced:	03 May 2025		
Hepatology Treatment		Co-medications	

Atorvastatin

Bulevirtide

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org .

Description of the interactions

Potential weak interaction - additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW)

Bulevirtide + Atorvastatin

Coadministration has not been studied. Atorvastatin is a substrate of CYP3A4, OATP1B1 and NTCP. Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. A clinical interaction study of high-dose bulevirtide (administered at 5 mg twice daily) showed a 1.34-fold increase of Cmax and AUC of pravastatin (40 mg single dose) a substrate of OATP1B1/3 and NTCP. A midazolam microdose was also applied during this study to quantify CYP3A4 activity which did not change to any clinically relevant extent. When bulevirtide is prescribed at the recommended dose of 2 mg, the risk for clinically relevant interactions with OATP1B1/3 / CYP3A4 and/or NTCP substrates is considered low. However, it should be noted that the product label recommends clinical monitoring if bulevirtide is coadministered with atorvastatin.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

This report is provided for information only. It is not intended to replace a consultation with an appropriately qualified the path probasional. Information presented relates only to known or suspected effects of interacting medications, and is based on relevand takin in the public domain. No clinical advice is given or implied, clinicians must exercise their own judgement in relation to the risks and benefits of combining drugs, which depend on factors beyond pharmacokinetic interactions between two drugs. The University of Liverpool and is not be held responsible for the application or use of any held in the public domain. No clinical advice is given or implied, the University of Liverpool and is not secure that information is accurate and consistent with current knowledge and phardacic. However, the University of Liverpool and is not be regarded to replace a consultation in any way liable for the continued the University of Liverpool and is not publication whether arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or otherwise however or for any consequences arising from negligence or